Earlier clinical scientific studies of CagriSema uncovered that it aided patients accomplish appreciably increased weight loss than semaglutide (Wegovy) did. even when Lilly's Zepbound/Mounjaro topples Wegovy, It is possible that CagriSema could enter the market at the right time for Novo Nordisk to retain its overall Management while in the weight